Intracellular interaction of von Willebrand factor and factor VIII depends on cellular context: Lessons from platelet-expressed factor VIII

Blood

Volumn 105, Issue 12, 2005, Pages 4674-4676

  Yarovoi, Helen ^b   Nurden, Alan T ^b   Montgomery, Robert R ^b   Nurden, Paquita ^b   Poncz, Mortimer ^a  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; PADGEM PROTEIN; VON WILLEBRAND FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOAVAILABILITY; BLEEDING TENDENCY; BLOOD CLOTTING; CAROTID ARTERY INJURY; CELL SECRETION; IMMUNOGOLD ELECTRON MICROSCOPY; INTRACELLULAR TRANSPORT; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN SECRETION; THROMBOCYTE ACTIVATION; TRANSGENIC MOUSE;

EID: 20444417088     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-12-4701     Document Type: Article

References (17)

1. Kufrin D, Eslin DE, Bdeir K, et al. Antithrombotic thrombocytes: ectopic expression of urokinase-type plasminogen activator in platelets. Blood. 2003;102:926-933.
2. Yarovoi H, Kufrin D, Eslin DE, et al. Factor VIII ectopically expressed in platelets: efficacy in hemophilia A treatment. Blood. 2003;102:4006-4013.
3. Kaufman RJ, Wasley LC, Davies MV, Wise RJ, Israel DI, Dorner AJ. Effect of von Willebrand factor coexpression on the synthesis and secretion of factor VIII in Chinese hamster ovary cells. Mol Cell Biol. 1989;9:1233-1242.
4. Miyazaki K, Reisine T, Kebabian JW. Adenosine 3′,5′- monophosphate (cAMP)-dependent protein kinase activity in rodent pituitary tissue: possible role in cAMP-dependent hormone secretion. Endocrinology. 1984;115:1933-1945.
5. Rosenberg JB, Foster PA, Kaufman RJ, et al. Intracellular trafficking of factor VIII to von Willebrand factor storage granules. J Clin Invest. 1998;101:613-624.
6. Denis C, Methia N, Frenette PS, et al. A mouse model of severe von Willebrand disease: defects in hemostasis and thrombosis. Proc Natl Acad Sci U S A. 1998;95:9524-9529.
7. Bi L, Lawler AM, Antonarakis SE, High KA, Gearhart JD, Kazazian HH Jr. Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A. Nat Genet. 1995;10:119-1121.
8. Herzog RW, Yang EY, Couto LB, et al. Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector. Nat Med. 1999;5:56-63.
9. Eslin DE, Zhang C, Samuels KJ, et al. Transgenic mice studies demonstrate a role for platelet factor 4 in thrombosis: dissociation between anticoagulant and antithrombotic effect of heparin. Blood. 2004;104:3173-3180.
10. Fay WP, Eitzman DT, Shapiro AD, Madison EL, Ginsburg D. Platelets inhibit fibrinolysis in vitro by both plasminogen activator inhibitor-1-dependent and -independent mechanisms. Blood. 1994;83:351-356.
11. Wilcox DA, Shi Q, Nurden P, et al. Induction of megakaryocytes to synthesize and store a releasable pool of human factor VIII. J Thromb Haemost. 2003;1:2477-2489.
12. Nurden P, Poujol C, Durrieu-Jais C, et al. Labeling of the internal pool of GPIIb-IIIa in platelets by c7E3 Fab fragments (abciximab): flow and endocytic mechanisms contribute to the transport. Blood. 1999;93:1622-1333.
13. Kaplan KL, Broekman MJ, Chernoff A, Lesznik GR, Drillings M. Platelet alpha-granule proteins: studies on release and subcellular localization. Blood. 1979;53:604-618.
14. Lamont PA, Ragni MV. Intracellular co-localization of Factor VIII and von Willebrand Factor is necessary for in vivo FVIII secretion [abstract]. Blood. 2004;104:15a. Abstract 41.
15. Xu L, Nichols TC, McCorquodale S, Dillow A, Merricks E, Ponder KP. DDAVP-induced increase of factor VIII activity in blood is likely due to release of factor VIII that is synthesized by endothelial cells [abstract]. Blood. 2004;104:199a. Abstract 692.
16. Pipe SW, Kaufman RJ. Characterization of a genetically engineered inactivation-resistant coagulation factor Villa. Proc Natl Acad Sci U S A. 1997;94:11851-11856.
17. Margaritis P, Arruda VR, Aljamali M, Camire RM, Schlachterman A, High KA. Novel therapeutic approach for hemophilia using gene delivery of an engineered secreted activated Factor VII. J Clin Invest. 2004;113:1025-1031.